SFEE: Need for stronger incentives for clinical trials in Greece
The Hellenic Association of Pharmaceutical Companies (SFEE) points out the need to take substantial measures that will strengthen clinical research in our country. According to the Association, Greece has the potential to become an important hub for international clinical trials, provided that the appropriate framework of incentives is created.
Clinical trials are a critical sector for both health and the economy. Through them, patients gain access to innovative treatments before they are widely available on the market, while at the same time the country's scientific potential and public health are strengthened.
However, SFEE emphasizes that international competition is intense. Many other European countries already offer more attractive tax and bureaucratic incentives, making it imperative to simplify procedures and increase research funding in Greece.
Strengthening this sector is expected to bring significant benefits, such as reducing costs for the healthcare system and attracting investments from major foreign pharmaceutical companies. Experts underline that investing in research is an investment in the future of medical care.
In conclusion, the initiative of SFEE highlights a significant opportunity for upgrading the Greek healthcare system. The State is now called upon to examine these proposals so that the country can become more competitive and offer better services to its citizens.